Aastrom Biosciences signs agreement with Mathys Medical for German bone graft clinical trial.Aastrom Biosciences, Inc, Ann Arbor Ann Arbor, city (1990 pop. 109,592), seat of Washtenaw co., S Mich., on the Huron River; inc. 1851. It is a research and educational center, with a large number of government and industrial research and development firms, many in high-technology fields such as , MI, announced that, through its wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. , Zellera AG, it has signed an agreement with Mathys Medical, Ltd., Bettlach, Switzerland, and Bergmannsheil University Clinic, Bochum, Germany, to begin the first collaborative clinical trial using the company's Tissue Repair Cells (TRCs) for bone graft bone graft Orthopedic surgery Sterilized bony tissue, often of cadaveric origin, used to fill and/or 'sculpt' bone defects Indications Spinal fusion, revision of failed articular prostheses, filling traumatic or malignant bone defects, or periodontal defects. applications. Aastrom says the bone graft clinical study will use the company's proprietary bone-forming TRCs in combination with Mathys' commercial synthetic bone graft matrix to treat patients with serious tibia tibia: see leg. fractures that require a bone graft for recovery. The trial, which expects to accrue 5 to 10 patients, will be conducted at Bergmannsheil University Clinic. In addition to the German trial, Aastrom says it is planning further trials and has submitted its lead bone graft trial plan to the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. . Contact: Kris Maly, Aastrom - (734) 930-5777, or Holger Beckmann, Zellera AG - (011-49-30-20659165) |
|
||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion